Table 3.
Survival outcomes assessed by IRC
| PD-L1 TPS ≥ 1% | PD-L1 TPS < 1% | HR (95% CI) | p-Value | Total (N = 27) | |
|---|---|---|---|---|---|
| Median PFS | 8.61 months | 4.73 months |
0.8 (0.27–2.35) |
0.6817 | 7.33 months |
| 95% CI | (1.61, -) | (3.61, 11.07) | (3.71–13.67) | ||
| Median OS | 26.14 months | 30.92 months |
1.1 (0.34–3.62) |
0.8717 | 30.92 months |
| 95% CI | (8.61, -) | (6.01, -) | (14.75, -) | ||
| 1-year OS rate | 75.0% | 66.7% | 73.9% | ||
| 95% CI | (31.5, 93.1) | (33.7, 86.0) | (50.9–87.3) | ||
| 2-year OS rate | 62.5% | 57.1% | 60.1% | ||
| 95% CI | (22.9, 86.1) | (25.4, 79.6) | (37.2–76.9) |
Survival analysis based on the Kaplan–Meier method was used for PFS and OS. A log-rank test was used to compare the difference in survival rate based on PD-L1 expression status. All p-values were two-sided.
IRC independent review committee, HR hazards ratio, 95% CI 95% confidence interval, PFS progression-free survival, OS overall survival.